Q3 performance: Multiple growth triggers for Jubilant Life Sciences

Further gains for stock will depend on listing of subsidiary, debt reduction

The Jubilant Life Sciences stock, which gained 11 per cent in two trading sessions on a strong December quarter (Q3), has sustained the high levels since then. The robust outlook for the March quarter and the next fiscal year are other factors that are keeping the Street’s sentiment elevated. Analysts have upgraded the stock and revised their sales and profitability estimates for the next two years as well. However, the stock might not see significant gains in the near term, given the recent rally.

The company, operating in the life sciences ingredients and pharmaceutical segments, reported a 42 per cent year-on-year